Subscribe
shutterstock_787266955_willy_barton
will barton / Shutterstock.com
25 July 2019Big PharmaSarah Morgan

Vaccines growth offsets Advair generic pain for GSK

Growth in GlaxoSmithKline’s (GSK) vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair (fluticasone propionate/salmeterol) on its sales.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
Americas
GSK sues Chinese company over Advair Diskus TMs
26 March 2019   Pharmaceutical company GSK has taken a Chinese company to court over its alleged “deliberate and unlawful campaign” to copy GSK’s trademarks.
Big Pharma
Ionis licenses chronic hepatitis B treatments to GSK
28 August 2019   Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
Americas
GSK sues Chinese company over Advair Diskus TMs
26 March 2019   Pharmaceutical company GSK has taken a Chinese company to court over its alleged “deliberate and unlawful campaign” to copy GSK’s trademarks.
Big Pharma
Ionis licenses chronic hepatitis B treatments to GSK
28 August 2019   Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline.

More on this story

Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
Americas
GSK sues Chinese company over Advair Diskus TMs
26 March 2019   Pharmaceutical company GSK has taken a Chinese company to court over its alleged “deliberate and unlawful campaign” to copy GSK’s trademarks.
Big Pharma
Ionis licenses chronic hepatitis B treatments to GSK
28 August 2019   Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York